{
  "pmcid": "9543254",
  "sha256": "e303fd0eefae51ed9caa538fabf61f899d5b6bac7d3101d4c9f7db721df1a5de",
  "timestamp_utc": "2025-11-09T16:21:34.988479+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.167046101309051,
    "reading_ease": 36.28899070385128,
    "word_count": 251
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "We conducted a double‐blind, randomised feasibility trial comparing peri‐operative angiotensin‐2 with noradrenaline."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "We randomly allocated 60 patients at two centres to a blinded equipotent angiotensin‐2 or noradrenaline infusion."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "We randomly allocated 60 patients at two centres to a blinded equipotent angiotensin‐2 or noradrenaline infusion intra‐operatively and for up to 48 h postoperatively."
      },
      "Objective": {
        "score": 1,
        "evidence": "We conducted a double‐blind, randomised feasibility trial comparing peri‐operative angiotensin‐2 with noradrenaline."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Primary feasibility outcomes included consent rate, protocol adherence, infusion duration, mean arterial pressure maintenance in the target range and major adverse outcomes."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "We randomly allocated 60 patients at two centres to a blinded equipotent angiotensin‐2 or noradrenaline infusion."
      },
      "Blinding": {
        "score": 2,
        "evidence": "We conducted a double‐blind, randomised feasibility trial."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "We randomly allocated 60 patients at two centres."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Acute kidney injury occurred in 7 of 28 in the angiotensin‐2 group vs. 12 of 32 patients in the noradrenaline group."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Acute kidney injury occurred in 7 of 28 in the angiotensin‐2 group vs. 12 of 32 patients in the noradrenaline group (p = 0.31)."
      },
      "Harms": {
        "score": 1,
        "evidence": "One participant had a stroke, one required extracorporeal support and three required renal replacement therapy, all in the noradrenaline group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}